Quarterly report pursuant to Section 13 or 15(d)

Debt and Interest

v3.21.2
Debt and Interest
6 Months Ended
Jun. 30, 2021
Debt and Interest  
Debt and Interest

10. Debt and Interest

Debt

Total debt consists of the following as of June 30, 2021 and December 31, 2020:

    

June 30, 

    

December 31,

    

    

($ in thousands)

2021

2020

Interest rate

Maturity

(Unaudited)

Total notes payable - Oaktree Note

$

60,000

$

60,000

 

11.00

%

August - 2025

Less: Discount on notes payable

 

(7,737)

 

(8,323)

 

  

 

  

Total notes payable

$

52,263

$

51,677

 

  

 

  

Oaktree Note

On August 27, 2020 (the “Closing Date”), Fortress, as borrower, entered into a $60.0 million senior secured credit agreement (the “Agreement”) with Oaktree.  The Oaktree Note bears interest at a fixed annual rate of 11.0%, payable quarterly and maturing on the fifth anniversary of the Closing Date, August 27, 2025, the (“Maturity Date”). The Company is required to make quarterly interest-only payments until the Maturity Date, at which point the outstanding principal amount is due. The Company may voluntarily prepay the Oaktree Note at any time subject to a Prepayment Fee as defined in the Terms section. The Company is required to make mandatory prepayments of the Oaktree Note under various circumstances as defined in the Terms section. No amounts paid or prepaid may be reborrowed without Oaktree consent.

Pursuant to the terms of the Agreement on the Closing Date the Company paid Oaktree an upfront commitment fee equal to 3% of the $60.0 million, or $1.8 million.  In addition, the Company paid a $35,000 Agency fee to the Agent which was due on the Closing Date and will be due annually, together with fees of $2.5 million, directly to third parties involved in the transaction.  

In connection with the Oaktree Note, the Company issued warrants to Oaktree and certain of its affiliates to purchase up to 1,749,450 shares of common stock (see Note 14) with a relative fair value of $4.4 million.

The Company recorded the fees totaling $8.7 million ($1.8 million to Oaktree, $2.5 million of expenses paid to third-parties and $4.4 million representing the relative fair value of the Oaktree Warrants) to debt discount.  These costs are being amortized over the term of the Oaktree Note.

Partner Company Installment Payments – Licenses

The following tables show the details of partner company installment payments – licenses for the periods presented.

June 30, 2021

($ in thousands)

    

Ximino 1

    

Accutane 2

    

Anti-Itch Product 3

    

Total

Partner company installment payments - licenses, short-term

$

2,000

$

1,000

$

1,500

$

4,500

Less: imputed interest

(517)

(101)

(21)

(639)

Sub-total partner company installment payments - licenses, short-term

$

1,483

$

899

$

1,479

$

3,861

Partner company installment payments - licenses, long-term

$

5,000

$

2,000

$

$

7,000

Less: imputed interest

(519)

(46)

(565)

Sub-total partner company installment payments - licenses, long-term

$

4,481

$

1,954

$

$

6,435

Total partner company installment payments - licenses

$

5,964

$

2,853

$

1,479

$

10,296

December 31, 2020

($ in thousands)

    

Ximino 1

    

Accutane 2

    

Anti-Itch Product 3

    

Total

Partner company installment payments - licenses, short-term

$

2,000

$

500

$

2,800

$

5,300

Less: imputed interest

(602)

(122)

(54)

(778)

Sub-total partner company installment payments - licenses, short-term

$

1,398

$

378

$

2,746

$

4,522

Partner company installment payments - licenses, long-term

$

5,000

$

3,000

$

1,000

$

9,000

Less: imputed interest

(775)

(88)

(863)

Sub-total partner company installment payments - licenses, long-term

$

4,225

$

2,912

$

1,000

$

8,137

Total partner company installment payments - licenses

$

5,623

$

3,290

$

3,746

$

12,659

Note 1:

Imputed interest rate of 11.96% and maturity date of July 22, 2024.

Note 2:  Imputed interest rate of 4.03%and maturity date of July 29, 2023.

Note 3:  Imputed interest rate of 4.25%and maturity date of January 1, 2022.

Interest Expense

The following table shows the details of interest expense for all debt arrangements during the periods presented. Interest expense includes contractual interest; fees include amortization of the debt discount and amortization of fees associated with loan transaction costs, amortized over the life of the loan.

Three Months Ended June 30, 

2021

2020

($ in thousands)

    

Interest

    

Fees1

    

Total

    

Interest

    

Fees1

    

Total

IDB Note

$

$

$

$

85

$

$

85

2017 Subordinated Note Financing

 

 

 

 

1,092

204

 

1,296

2019 Notes

269

269

2018 Venture Notes

 

 

 

 

433

186

 

619

LOC Fees

 

14

 

 

14

 

16

 

16

Mustang Horizon Notes

 

 

 

 

349

270

 

619

Oaktree Note

1,669

324

1,993

Partner company convertible preferred shares

270

270

Partner company dividend payable

263

263

Partner company installment payments - licenses 2

220

220

155

155

Other

 

 

 

 

 

 

Total Interest Expense and Financing Fee

$

2,166

$

594

$

2,760

$

2,399

$

660

$

3,059

Six Months Ended June 30, 

2021

2020

($ in thousands)

    

Interest

    

Fees1

    

Total

    

Interest

    

Fees1

    

Total

IDB Note

$

$

$

$

169

-

$

169

2017 Subordinated Note Financing

 

 

 

 

2,176

516

 

2,692

2019 Notes

 

 

 

 

538

 

538

2018 Venture Notes

 

 

 

 

866

362

 

1,228

LOC Fees

 

23

 

 

23

 

31

 

31

Mustang Horizon Notes

 

 

 

 

690

529

 

1,219

Oaktree Note

3,319

633

3,952

Partner company convertible preferred shares

270

270

Partner company dividend payable

263

263

Partner company installment payments - licenses 2

441

441

305

305

Other

 

 

 

 

2

2

Total Interest Expense and Financing Fee

$

4,046

$

903

$

4,949

$

4,777

$

1,407

$

6,184

Note 1:

Amortization of fees in connection with debt raises.

Note 2: Imputed interest expense related to Ximino, Accutane and inti-itch cream acquisitions.  

Journey Working Capital Line of Credit

On March 31, 2021 (the “Closing Date”), Journey entered into a Loan and Security Agreement with East West Bank (“EWB Loan”) under which Journey may request advances in aggregate not exceeding the lesser of: (i) the Revolving Line of $7.5 million and (ii) a Borrowing Base representing approximately 85% of Journey’s eligible accounts receivable.  Advances bear interest on the outstanding daily balance, at a floating rate of 1.0% above the Prime Rate set by EWB.  Interest is due and payable on the last day of the month. The EWB Loan matures on March 31, 2024.

Journey paid an origination fee of $56,250 on the Closing Date in connection with the issuance of the EWB Loan. In addition, Journey agreed to pay certain third party fees incurred by EWB, as well as legal fees incurred by Journey in connection with the EWB Loan totaling approximately $0.1 million. As of June 30, 2021 fees totaling approximately $0.1 million were recorded as a deferred asset on the condensed consolidated balance sheet. As of June 30, 2021 Journey had no outstanding advances under the EWB Loan.